DGX · Categories · Upgrades
DGX - Analyst upgrades
Quest Diagnostics Incorporated (DGX) analyst upgrades - real-time wire coverage filtered to Upgrades only.
Recent Upgrades for DGX
- Quest Diagnostics upgraded by Barclays with a new price targetBarclays upgraded Quest Diagnostics from Equal Weight to Overweight and set a new price target of $210.00
- Quest Diagnostics upgraded by Leerink Partners with a new price targetLeerink Partners upgraded Quest Diagnostics from Market Perform to Outperform and set a new price target of $174.00 from $169.00 previously
- Quest Diagnostics upgraded by Morgan Stanley with a new price targetMorgan Stanley upgraded Quest Diagnostics from Equal-Weight to Overweight and set a new price target of $172.00 from $145.00 previously
- Quest Diagnostics upgraded by Robert W. Baird with a new price targetRobert W. Baird upgraded Quest Diagnostics from Neutral to Outperform and set a new price target of $182.00 from $157.00 previously
- Quest Diagnostics upgraded by Citigroup with a new price targetCitigroup upgraded Quest Diagnostics from Neutral to Buy and set a new price target of $165.00 from $145.00 previously
- Quest Diagnostics upgraded by Jefferies with a new price targetJefferies upgraded Quest Diagnostics from Hold to Buy and set a new price target of $155.00 from $140.00 previously
- Quest Diagnostics upgraded by BofA Securities with a new price targetBofA Securities upgraded Quest Diagnostics from Neutral to Buy and set a new price target of $160.00 from $140.00 previously
- Quest Diagnostics upgraded by Citigroup with a new price targetCitigroup upgraded Quest Diagnostics from Sell to Neutral and set a new price target of $142.00 from $125.00 previously
- Quest Diagnostics upgraded by UBS with a new price targetUBS upgraded Quest Diagnostics from Neutral to Buy and set a new price target of $158.00 from $135.00 previously